anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Preeclampsia, the more severe manifestation of gestational hypertensive disorders, is a major cause of maternal and perinatal morbidity and mortality worldwide. Genetic polymorphisms in long non-coding RNAs (lncRNAs) are considered as potential genetic preeclampsia. This study aimed to explore the association between SENCR rs555172 SNP and PE risk in healthy pregnant women compared to women with preeclampsia. A total of 140 healthy pregnant women and 130 preeclampsia cases were included in the study. The rs555172 genotype was determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and the expression of the SENCR gene was analyzed in 40 placenta tissue samples from both groups. Various statistical approaches were employed to assess the genotypic and allelic frequencies. The results showed no significant difference in the frequency of the rs555172 polymorphism between healthy pregnant women and those with preeclampsia in terms of the dominant (p=0.82), recessive (p=0.39), and over-dominant (p=0.42) models. Additionally, the analysis of SENCR relative expression revealed no significant difference between the two groups (p=0.48). In conclusion, the LncRNA SENCR rs555172(G/A) seems not associated with an increased risk of Preeclampsia in pregnant women.
This group will provide 8 weeks of multi-family psychoeducation to the families of people living with a diagnosis of substance abuse disorder after the intervention group is completed. This group is the control group on the waiting list.
Older patients have been remarkably underrepresented in bleeding risk cohorts. Thus, the PRECISE-DAPT (Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy) and Academic Research Consortium for High Bleeding Risk (ARC-HBR) scores are not validated in older adults. Therefore, we sought to evaluate the PRECISE-DAPT and ARC-HBR scores in an exclusively older population and assess the prognostic value of a truly simplified clinical evaluation (SCE), consisting of only 3 binary clinical variables (hemoglobin <11 g/100 ml, previous bleeding, and anticipated use of anticoagulants). This is a retrospective analysis of the prospective single-center older-HCD registry. Consecutive patients aged ≥75 years who underwent percutaneous coronary intervention from 2012 to 2019 were included. The primary end point was postdischarge bleeding at 12 months of follow-up, defined according to the Bleeding Academic Research Consortium 3 or 5 criteria. A total of 693 patients with a mean age of 81 (±4.4) years were included in the study and 60 patients (6.8%) met the primary end point. The PRECISE-DAPT and ARC-HBR scores did not significantly predict postdischarge bleeding in the Cox regression models (hazard ratio 1.65 [0.78 to 3.42] and 1.46 [0.72 to 4.24], respectively), whereas the SCE outperformed both scores (hazard ratio 2.47, 1.34 to 4.49). All 3 scores exhibited a moderate discriminatory potential, as determined by a receiver-operating characteristic curve analysis (areas under the curve 0.601, 0.621, and 0.616, respectively), with no significant differences between them. The SCE showed an Integrated Discrimination Improvement of 0.25, p = 0.02 (SCE vs ARC-HBR) and 0.24, p = 0.01 (SCE vs PRECISE-DAPT), with an Net Reclassification Improvement of 6.54%, p = 0.37 and 7.12%, p = 0.43, respectively. In conclusion, the PRECISE-DAPT score and ARC-HBR criteria showed insufficient predictive value in older adults. A truly SCE consisting of 3 easily accessible variables not only provides equal discriminatory potential but also demonstrates superior predictive value, as determined by Cox regression models. This makes it a highly appealing tool for risk stratification, pending its evaluation in larger prospective studies.
The first study on the Hall Technique was published in 2006 . It was a retrospective study which analysed the practice records of a general dental practitioner from Scotland, Dr. Norna Hall. Dr. Hall simplified the standard technique to restore primary teeth using preformed SSCs and used it with her patients. This retrospective study involved a total of 978 crowns fitted in 259 children using her novel technique (today known as the Hall Technique). Most crowns were placed when there was clinical evidence of a proximal carious lesion into dentine and marginal ridge breakdown. This study showed the Hall Technique to have comparable outcomes to those achieved with other more conventional restorations.

Since then, growing understanding that caries is essentially a biofilm driven disease rather than an infectious disease, explains why the Hall Technique, and other 'sealing in' carious lesion techniques, are successful. The intervening ten years has seen robust evidence from several randomised control trials that are either completed or underway. These have found the Hall Technique superior to comparator treatments, with success rates (no pain or infection) of 99% (UK study) and 100% (Germany) at one year, 98% and 93% over two years (UK and Germany) and 97% over five years (UK). The Hall Technique is now regarded as one of several biological management options for carious lesions in primary molars.
OBJECTIVE: To evaluate phytochemicals and in vitro biological potential of flowers, leaves and stem extracts of Rosa arvensis.
METHODS: Presence of twenty secondary metabolites was confirmed and then phenolic and flavonoid contents were quantified spectrophotometrically. Fourier Transform Infrared spectroscopy was conducted to ascertain functional groups and antioxidant potential was examined using 2,2-diphenyl-1-picrylhydrazyl scavenging activity, total antioxidant capacity and total reducing power assays. Human erythrocytes were used to assess anti-hemolytic activity and five bacterial strains were examined to determine antibacterial potential of plant extracts. Radish seeds were used to perform phytotoxic activity and cytotoxic potential was evaluated via brine shrimps and PC3 cell lines.
RESULTS: Highest phenolic contents were detected in the methanolic extract of Rosa arvensis flower (RAFM) [(151.635 ± 0.005) gallic acid equivalent mg/g] and highest flavonoid contents in the chloroform leaf extract (RALC) [(108.228 ± 0.004) quercetin equivalent mg/g]. Fourier-transform infrared spectroscopy analysis showed the presence of wide range of functional groups. The antioxidant assays indicated highest DPPH scavenging activity [IC50 (23.5 ± 0.6) μg/mL] in the methanolic stem extract (RASM), highest total antioxidant capacity [(265.1 ± 0.9) μg/mL] in RAFM and highest reducing potential [(209.9 ± 0.6) μg/mL] in leaf extract (RALM). Highest anti-hemolytic activity [(90.0 ± 0.5) μg/mL] was recorded in RAFM and brine shrimp cytotoxicity potential [(52.3 ± 0.3) μg/mL] in RASM. The antimicrobial activity was detected highest [(21.1 ± 0.5) mm inhibition zones] in RALM against Streptococcus aureus. In the end, anti-inflammatory and anti-cancer activity results depicted less than 50 % inhibition in the methanolic extracts. CONCLUSIONS: Our findings will be helpful in designing pharmaceutical regimens and therefore, more studies can be recommended to isolate and characterize compounds associated with the biological activities of Rosa arvensis.
A new anticarcinogenic sustained-release injection consists of sustained-release microballoon sphere and menstruum; wherein, the sustained-release microballoon sphere comprises anticarcinogenic active ingredient and sustained-release accessory material; the menstruum is special menstruum containing suspending agent. The anticarcinogenic active ingredient is the combination of cytotoxic drugs of fotemustine, bendamustine, tallimustine, carmustinum, nimustine, lomustine, semustine or ranimustine and adriamycin, epirubicin, melphalan, 4H peroxide cyclophosphamide, actinomycin D, vinorelbine or nolvadex, etc.; the sustained-release accessory material is selected from polylactic acid and the multipolymer or mixture thereof, mono-methyl polyethyleneglycol, polyethyleneglycol or polylactic acid multipolymer, EVAc, the multipolymer of fatty acid and decanedioic acid, etc.; the viscosity of the suspending agent is 100cp-3000cp (at the temperature of 25 DEG C-30 DEG C), the suspending agent is selected from sodium carboxymethyl cellulose, etc. The sustained-release microballoon sphere also can be made into sustained-release implant which can be injected and placed in tumor or around tumor and can release medicine at the local parts of the tumor for 30 to 40 days; therefore, the anticarcinogenic sustained-release injection can be separately united together with non-operativetreatment such as chemo-treatment and/or radiation treatment, etc. for application.
The present invention relates to the use of four glyosidic iridoids (geniposides, geniposidic acid, loganin, and loganic acid) for the treatment of cervical cancer. Said geniposide decreases the expression of the E6 gene by 80% and in a 60% expression of E7, both involved in the malignant transformation of cervical keratinocytes. Also, geniposidic acid decreases the expression of the E7 gene. Said agents characterizes by reversing the damage caused by the human papillomavirus on the cell, thus attacking in a specific way the tumor cells and not the normal ones. Further, it has higher potency and less amount of glucosides iridoids for achieving the same biological effect of the current treatment. The present invention aims to reduce adverse effects and improve the quality of life of patients.
Voluntary participants between the ages of 18-65 who have been diagnosed with CTS will be included in the study.The 7 steps in the Clinical Criteria/Rating System determined by the International Association for the Study of Pain (IASP) for Nosiplastic Pain and Carpal Tunnel Syndrome will be applied to people with CTS. Pressure pain threshold, thermal pain threshold, mechanical pain sensitivity and allodynia will be evaluated to determine pain hypersensitivity (Step 5). Specific questions will be asked to confirm the history of hypersensitivity in patients (Step 6). Finally, comorbidities, if any, will be determined (Step 7). As a result, the pain phenotype of patients with CTS will be determined (Nociceptive, Neuropathic or Nosiplastic). Shapiro-Wilk test will be performed to determine the distribution of the data. One-way ANOVA (continuous) or Kruskal-Wallis (categorical) will be used to examine whether the dependent variables differ between groups. For significant F-test, an additional investigation of differences between groups will be performed with Gabriel's post hoc procedure.
AIMS: This study was designed to evaluate the magnetic resonance imaging (MRI) patterns of the lower limb muscles in dermatomyositis (DM) with anti-transcriptional intermediate factor 1-γ (anti-TIF1-γ) antibody.
METHODS: This retrospective, observational, cross-sectional study enrolled 12 adult DM patients with anti-TIF1-γ antibody. Muscles were assessed for fascial edema, subcutaneous-tissue edema, muscle edema, and fatty replacement. These features were analyzed in relation to clinical characteristics.
RESULTS: All 12 patients underwent hip and thigh MRI, and 8 completed calf MRI. All patients showed myofascial edema, muscle edema, and fatty replacement, and 8 out of 12 further exhibited subcutaneous-tissue edema. Specifically, myofascial edema of the gastrocnemius was observed in all patients (8/8). The vastus intermedialis and vastus lateralis muscles showed the most severe muscle edema, whereas the caput breve of the biceps femoris, semitendinosus, and soleus muscles exhibited the most severe fatty replacement. Although only 1 patient exhibited asymmetric muscle weakness, 9 showed asymmetric muscle edema, and 10 showed asymmetric fatty replacement. Changes in muscle edema positively correlated with creatine kinase (CK) levels.
CONCLUSIONS: Myofascial edema of gastrocnemius was a prominent characteristic of anti-TIF1-γ-positive DM. Early detection of muscle edema, as well as CK levels, may be helpful for monitoring disease activity.
A method of personalizing at least one hearing aid for a hearing aid user including manufacturing at least one hearing aid (1), receiving an audiogram from a server (37) for the hearing aid user, programming the at least one hearing aid (1) by the audiogram, whereby the at least one hearing aid (1) becomes personalized for the hearing aid user. The at least one personalized hearing aid (1) is delivered to the hearing aid user. Once the user has received the at least one personalized hearing aid (1), he may take the hearing aids into use. If there arises a need for fine tuning, the hearing aid user may request a consultation with a hearing healthcare professional. The hearing healthcare professional has equipment (44, 45) for fine tuning the hearing aid (1), and he may fine tuning the at least one personalized hearing aid (1) in dialogue with the hearing aid user. Also provided is a hearing aid delivering system and an Internet enabled personal communication device.
Patients will be screened up to seven days at which time the following assessments will be completed: the Structured Clinical Interview for DSM-IV (SCID), general medical history, psychiatric history, physical examination, physicians assessment, and laboratory tests. Patients who are on mood stabilizers and oral neuroleptics prior to study enrollment and are not responding fully to these medications will be tapered off of the medication for a washout period of 48 hours. After the completion of screening, only patients who are determined to be eligible for the study will be randomized to study medication (divalproex or risperidone) in a 1:1 double-blind fashion. Scheduled study visits will occur every two weeks for a total of 12 weeks. Assessments for each visit, from the baseline visit to the week 12 visit are as follows: the Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), Alcohol and Drug Use Inventory, clinician alcohol and drug use scales, self report scales, adverse events, vital signs and weight, concomitant medications, urine drug screen, and study medication accountability. Designated research staff will complete assessments weekly. Investigators will be blinded to laboratory tests completed at week 2, 4, and 12 visits. Patients randomized to Depakote ER will begin 500mg BID on day of randomization and remain on this dose for 5 days, then on day 6 increase to 20mg/kg to achieve valproic acid levels of 80-100 (blinded laboratory reporting). Patients randomized to risperidone, initially start with 2mg QD with an increase to 4mg at day 5 and increase (as tolerated or required) up to 6mg/d.
NEW MATERIAL:A pyridine derivative shown by the formula I (R<1> is lower alkyl; R<2> is H, carboxyl, or lower alkyloxycarbonyl; n is 1-20). EXAMPLE:10(1, 2-Dihydro-4-hydroxy-3-methoxy-1-methyl-2-oxo-6-pyrdinyl)methyloxydecanoic acid ethyl ester. USE:A drug for circulatory system. A hypotensive, having vasodilating action on coronary vessel and inhibitory action on blood platelet aggregation. PROCESS:A compound shown by the formula II is treated with a compound shown by the formula III (X is halogen; A is H or lower alkyloxycarbonyl) and an alkali hydride, an subjected to debenzylation to give a compound shown by the formula I where R<2> is A. A compound shown by the formula IV is hydrolyzed to give a compound shown by the formula I where R<2> is COOH.
BACKGROUND: The relation of adipose tissue depletion with prognostic outcome of variceal bleeding among cirrhotic patients is still inconclusive. The present work explored whether adipose tissue, which was measured based on computed tomography (CT), was valuable for analyzing rebleeding and mortality among patients with variceal bleeding who had undergone endoscopic therapy.
METHODS: The study encompassed cirrhotic patients who underwent endoscopic therapy to prevent variceal rebleeding between January 2016 and October 2022. The L3-level CT images were obtained. Besides, impacts of subcutaneous adipose tissue index (SATI), visceral adipose tissue index (VATI), as well as total adipose tissue index (TATI) on rebleeding and mortality among cirrhotic patients following endoscopic therapy were examined.
RESULTS: In this work, our median follow-up period was 31 months. Among those adipose tissue indexes, only SATI exhibited an independent relation to higher rebleeding (HR 0.981, 95% CI, 0.971-0.991, p < 0.001) and mortality (HR 0.965, 95% CI, 0.944-0.986, p = 0.001) risks. Upon multivariate Cox regression, low SATI (male < 30.15 cm2/m2, female < 39.82 cm2/m2) was independently linked to higher rebleeding risk (HR 2.511, 95% CI, 1.604-3.932, p < 0.001) and increased mortality risk (HR 3.422, 95% CI, 1.489-7.864, p = 0.004) after adjusting for other predictors. Furthermore, subgroups were created based on using nonselective β-blockers (NSBBs), demonstrating that quantitatively assessing SATI exerts a vital role in evaluating rebleeding incidence in patients with or without NSBB therapy.
CONCLUSION: This study underscores the potential of quantifying SATI as a means for achieving a more accurate risk classification for individual patients and identifying patients that can gain more benefits from nutritional intervention.
Despite emerging public concern regarding the sleep health of military personnel over the past two decades, there remains a dearth of research examining sleep health among naval personnel assigned to sea duty. This study examined sleep metrics (e.g. fatigue, short sleep duration) and mental (e.g. posttraumatic stress disorder, depression) and physical health (e.g. type 2 diabetes, bodily pain) outcomes among naval personnel with recent sea duty (i.e. afloat) compared with naval personnel with recent shore duty (i.e. ashore). Prevalence ratios and mean differences for all outcomes were estimated and adjusted for demographic and military variables, and subsequently stratified by obesity. Sleep metrics were similar between afloat and ashore sailors except for short sleep duration, while sailors with recent shore duty had poorer physical health compared with those with recent sea duty. Stratified analyses suggested naval personnel with obesity had a higher proportion of nearly all adverse sleep-related health outcomes than those without obesity. Among participants without obesity, afloat personnel were more likely to report very short sleep (≤ 5 hours) and fewer hours of average nightly sleep, but were less likely to report physical health outcomes compared with ashore personnel. These findings suggest potential differences in sleep metrics and sleep-related health outcomes between afloat and ashore naval personnel. Additional research examining sleep outcomes using more objective measures is required to further investigate these findings, which may inform strategies to foster consolidated sleep despite environmental and occupational challenges in order to maintain high-performing naval personnel.
During the waiting period, patients receive no treatment. After a waiting time of 2 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
PROBLEM TO BE SOLVED: To obtain subject composition useful for treating the enterobiasis of human or non-human animal bodies, especially for treating the invasion of nematodes into the bodies of livestock and other rearing animals by compounding a specific anthelmintic activity compound. SOLUTION: This medicinal composition contains (B) at least one kind of anthelmintic activity compound comprising avermectin or milbemycin as (A) at least one kind of complex with cyclodextrin. The component B preferably comprises the avermectin, the milbemycin or a compound expressed by the partial formula [R<1> is (substituted) amino, imino, etc.; R<2> -R<5> are each H or an organic radical], especially 5-oximino-22,23-dihydro-25-cycloexylavermectin B1 monosacharide. The component A is preferably β-cyclodextrin or dimethyl β-cyclodextrin. It is preferable that a component B: component A ratio is 1:1 to 1:10 (w/w).
PURPOSE:To facilitate the reading of whether the condition of a patient gets better or worse by a medical action to the patient by a physician by extracting a data desired to be compared from a data base having various medical activities and various results of inspection stored to present the various medical activities and various results of inspection in a time-series correspondence to each other. CONSTITUTION:When a display period, medical activities and results of inspection desired to be displayed in correspondence are assigned, the period, medical activities and inspection items are retrieved from a third data base to match. Then, the data retrieved is sorted in the sequence of data and the results of inspection are displayed in a line graph with values of the results of inspection taken on the vertical axis and date of implementation on the horizontal axis so as to be held within a display area based on unit information and values of the results of inspection. Regarding the medical activities, medical care implementation items and numeral data are displayed at the left end thereof and a symbol indicating implementation is displayed at a position corresponding to the date of implementation (or period of implementation). Here, the date on the results of inspection is made the same as that of the medical activities. This facilitates the reading of the medical activities and correlation of the results therewith.
Preoperative risk biomarkers for delirium may aid in identifying high-risk patients and developing intervention therapies, which would minimize the health and economic burden of postoperative delirium. Previous studies have typically used single omics approaches to identify such biomarkers. Preoperative cerebrospinal fluid (CSF) from the Healthier Postoperative Recovery study of adults ≥ 63 years old undergoing elective major orthopedic surgery was used in a matched pair delirium case-no delirium control design. We performed metabolomics and lipidomics, which were combined with our previously reported proteomics results on the same samples. Differential expression, clustering, classification, and systems biology analyses were applied to individual and combined omics datasets. Probabilistic graph models were used to identify an integrated multi-omics interaction network, which included clusters of heterogeneous omics interactions among lipids, metabolites, and proteins. The combined multi-omics signature of 25 molecules attained an AUC of 0.96 [95% CI: 0.85-1.00], showing improvement over individual omics-based classification. We conclude that multi-omics integration of preoperative CSF identifies potential risk markers for delirium and generates new insights into the complex pathways associated with delirium. With future validation, this hypotheses-generating study may serve to build robust biomarkers for delirium and improve our understanding of its pathophysiology.
An examination system is provided. The examination system includes an optical detector and analyzer. The optical detector emits a detection light source toward a target object and detects a respondent light which is induced from the target object in response to the detection light source to generate image data. The image data indicates a detection image. The analyzer receives the image data and determines which region of the target object the detection image belongs to according to the image data. When the analyzer determines that the detection image belongs to a specific region of the target object, the analyzer extracts at least one feature of the image data to serve as a basis for classification of the specific region.